Recent advances in antileishmanial drug development

Current Opinion in Investigational Drugs

Volumn 6, Issue 2, 2005, Pages 163-169

  Davis, Antony J ^a   Kedzierski, Lukasz ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Antimicrobial peptides; Leishmania; Leishmaniasis; Natural products; Pentavalent antimonials; Treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; CECROPIN A; DERMASEPTIN; DIAMIDINE DERIVATIVE; DIAMIDINE PENTAMIDINE; FLUCONAZOLE; GENTAMICIN; IMIQUIMOD; INDOLICIDIN; ITRACONAZOLE; KETOCONAZOLE; MAGAININ 1; MEGLUMIN ANTIMONIATE; MELITTIN; MILTEFOSINE; PAROMOMYCIN; PENTAVALENT ANTIMONIAL; PEPTIDE CECROPIN A MELITTIN HYBRID PEPTIDE; PEPTIDE DERMASEPTIN S4; PEPTIDE GOMESIN; PEPTIDE TEMPORIN A; PEPTIDE TEMPORIN B; PEPTIDE YY; POLYPEPTIDE ANTIBIOTIC AGENT; SITAMAQUINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; BIOLOGICAL FACTOR;

ANTIBIOTIC RESISTANCE; BURN; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFLAMMATION; LEISHMANIA PANAMENSIS; LEISHMANIASIS; NONHUMAN; REVIEW; SIDE EFFECT; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; ANIMAL; PARASITOLOGY; PHYTOTHERAPY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; BIOLOGICAL FACTORS; HUMANS; LEISHMANIASIS; PHYTOTHERAPY;

EID: 15744385718     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Handman E: Cell biology of Leishmania. Adv Parasitol (1999) 44:1-39.
2. Desjeux P: Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis (2004) 27(5):305-318.
3. World Health Organization: The leishmaniases and Leishmania/HIV co-infections. (2004): Fact sheet 116. http://www.who.int/mediacentre/ factsheets/fs116/en/
4. Handman E, Bullen DV: Interaction of Leishmania with the host macrophage. Trends Parasitol (2002) 18(8):332-334.
5. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, Villarroel H, Zapata Z, Tomedes I: Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg (2003) 97(4):469-472.
6. Handman E: Leishmaniasis: Current status of vaccine development. Clin Microbiol Rev (2001) 14(2):229-243.
7. Murray HW: Progress in the treatment of a neglected infectious disease: Visceral leishmaniasis. Expert Rev Anti Infect Ther (2004) 2(2):279-292. A thorough review of developments in the treatment of visceral leishmaniasis over the last ten years.
8. Davis AJ, Murray HW, Handman E: Drugs against leishmaniasis: A synergy of technology and partnerships. Trends Parasitol (2004) 20(2):73-76.
9. Croft SL, Coombs GH: Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol (2003) 19(11):502-508.
10. Berman J: Current treatment approaches to leishmaniasis. Curr Opin Infect Dis (2003) 16(5):397-401.
11. Sundar S, Rai M: Advances in the treatment of leishmaniasis. Curr Opin Infect Dis (2002) 15(6):593-598.
12. World Health Organization: WHO model prescribing information: Drugs used in parasitic diseases. Geneva, Switzerland (1995):2.
13. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW: Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin Infect Dis (2000) 31(4):1104-1107.
14. Sundar S: Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 6(11):849-854.
15. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD: Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ (1998) 76(1):25-32.
16. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J: Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 347(22):1739-1746.
17. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis (2001) 33(7):E57-E61.
18. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K et al: Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis (2004) 38(9):1266-1272.
19. Perez-Victoria FJ, Castanys S, Gamarro F: Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother (2003) 47(8):2397-2403.
20. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S: Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem (2003) 278(50):49965-49971.
21. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg (2000) 94(4):432-433.
22. el-On J, Halevy S, Grunwald MH, Weinrauch L: Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major. A double-blind control study. J Am Acad Dermatol (1992) 27(2 Pt 1):227-231.
23. Soto JM, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase 2 pilot study. Am J Trop Med Hyg (2002) 66(2):147-151.
24. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R: Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop (2004) 91(2):153-160.
25. Bryceson AD, Murphy A, Moody AH: Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: Results of an open study in London. Trans R Soc Trop Med Hyg (1994) 88(2):226-228.
26. Grogl M, Schuster BG, Ellis WY, Berman JD: Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol (1999) 85(2):354-359.
27. Mandelbaum-Schmid J: New generation of non-profit initiatives tackles world's 'neglected' diseases. Bull World Health Organ (2004) 82(5):395-396.
28. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, Wasunna KM, Were JB, Kasili SK, Mbugua JM et al: Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis (1994) 19(6):1034-1039.
29. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M: Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg (2001) 65(6):685-689.
30. Yeates C: Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Investig Drugs (2002) 3(10):1446-1452.
31. Berman JD, Gallalee JV: In vitro antileishmanial activity of inhibitors of steroid biosynthesis and combinations of antileishmanial agents. J Parasitol (1987) 73(3):671-673.
32. Beach DH, Goad LJ, Holz GG Jr: Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol (1988) 31(2):149-162.
33. Hart DT, Lauwers WJ, Willemsens G, Vanden Bossche H, Opperdoes FR: Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages. Mol Biochem Parasitol (1989) 33(2):123-134.
34. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Fans RM, Maguire JH: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med (2002) 346(12):891-895.
35. Calvopina M, Guevara AG, Armijos RX, Hashiguchi Y, Davidson RN, Cooper PJ: Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int J Dermatol (2004) 43(9):659-663.
36. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC: Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother (1999) 43(12):2910-2914.
37. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA: Cytokine induction in mice by the immunomodulator imiquimod. J Leukocyte Biol (1994) 55(2):234-240.
38. Tomai MA, Gibson SJ, Imbertson LM, Miller RL, Myhre PE, Reiter MJ, Wagner TL, Tamulinas CB, Beaurline JM, Gerster JF, Horton VL: Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res (1995) 28(3):253-264.
39. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, Wagner TL, Tomai MA: Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukocyte Biol (1995) 58(3):365-372.
40. Buates S, Matlashewski G: Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action. J Infect Dis (1999) 179(6):1485-1494.
41. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, Matlashewski G, Llanos-Cuentas A: Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis (2001) 33(11):1847-1851.
42. Seeberger J, Daoud S, Pammer J: Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int J Dermatol (2003) 42(7):576-579.
43. Zasloff M: Antimicrobial peptides of multicellular organisms. Nature (2002) 415(6870):389-395.
44. Nicolas P, Mor A: Peptides as weapons against microorganisms in the chemical defense system of vertebrates. Annu Rev Microbiol (1995) 49:277-304.
45. Vizioli J, Salzet M: Antimicrobial peptides versus parasitic infections? Trends Parasitol (2002) 18(11):475-476.
46. Vouldoukis I, Shai Y, Nicolas P, Mor A: Broad spectrum antibiotic activity of the skin-PYY. FEBS Lett (1996) 380(3):237-240.
47. Feder R, Dagan A, Mor A: Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity. J Biol Chem (2000) 275(6):4230-4238.
48. Kustanovich I, Shalev DE, Mikhlin M, Gaidukov L, Mor A: Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J Biol Chem (2002) 277(19):16941-16951.
49. Gaidukov L, Fish A, Mor A: Analysis of membrane-binding properties of dermaseptin analogues: Relationships between binding and cytotoxicity. Biochemistry (2003) 42(44):12866-12874.
50. Akuffo H, Hultmark D, Engstom A, Frohlich D, Kimbrell D: Drosophila antibacterial protein, cecropin A, differentially affects non-bacterial organisms such as Leishmania in a manner different from other amphipathic peptides. Int J Mol Med (1998) 1(1):77-82.
51. Diaz-Achirica P, Ubach J, Guinea A, Andreu D, Rivas L: The plasma membrane of Leishmania donovani promastigotes is the main target for CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide. Biochem J (1998) 330(1):453-460.
52. Silva PI Jr, Daffre S, Bulet P: Isolation and characterization of gomesin, an 18-residue cysteine-rich defense peptide from the spider Acanthoscurria gomesiana hemocytes with sequence similarities to horseshoe crab antimicrobial peptides of the tachyplesin family. J Biol Chem (2000) 275(43):33464-33470.
53. Bera A, Singh S, Nagaraj R, Vaidya T: Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol Biochem Parasitol (2003) 127(1):23-35.
54. Guerrero E, Saugar JM, Matsuzaki K, Rivas L: Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob Agents Chemother (2004) 48(8):2980-2986.
55. Mangoni ML, Saugar JM, Dellisanti M, Barra D, Simmaco M, Rivas L: Temporins: Small antimicrobial peptides with leishmanicidal activity. J Biol Chem (2005) 280(5):984-990.
56. Roch P, Beschin A, Bernard E: Antiprotozoan and antiviral activities of non-cytotoxic truncated and variant analogues of mussel defensin. Evid Based Complement Alternat Med (2004) 1(2):167-174.
57. Alberola J, Rodriguez A, Francino O, Roura X, Rivas L, Andreu D: Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob Agents Chemother (2004) 48(2):641-643. This paper describes a small animal trial conducted in dogs testing the efficacy of a synthetic antimicrobial peptide against canine leishmaniasis.
58. Yang D, Biragyn A, Kwak LW, Oppenheim JJ: Mammalian defensins in immunity: More than just microbicidal. Trends Immunol (2002) 23(6):291-296.
59. Salzet M: Antimicrobial peptides are signaling molecules. Trends Immunol (2002) 23(6):283-284.
60. Chan-Bacab MJ, Pena-Rodriguez LM: Plant natural products with leishmanicidal activity. Nat Prod Rep (2001) 18(6):674-688.
61. Fournet A, Munoz V: Natural products as trypanocidal, antileishmanial and antimalarial drugs. Curr Top Med Chem (2002) 2(11):1215-1237. A review summarizing the current status of natural products against parasitic diseases and recent developments in this field.
62. Kayser O, Kiderlen AF, Croft SL: Natural products as antiparasitic drugs. Parasitol Res (2003) 90(Suppl 2):S55-S62.
63. Muhammad I, Dunbar DC, Khan SI, Tekwani BL, Bedir E, Takamatsu S, Ferreira D, Walker LA: Antiparasitic alkaloids from Psychotria klugii. J Nat Prod (2003) 66(7):962-967.
64. Sairafianpour M, Christensen J, Staerk D, Budnik BA, Kharazmi A, Bagherzadeh K, Jaroszewski JW: Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: New source of tanshinones. J Nat Prod (2001) 64(11):1398-1403.
65. Fuchino H, Koide T, Takahashi M, Sekita S, Satake M: New sesquiterpene lactones from Elephantopus mollis and their leishmanicidal activities. Planta Med (2001) 67(7):647-653.
66. Barata LE, Santos LS, Ferri PH, Phillipson JD, Paine A, Croft SL: Antileishmanial activity of neolignans from Virola species and synthetic analogues. Phytochemistry (2000) 55(6):589-595.
67. Kayser O, Kiderlen AF, Laatsch H, Croft SL: In vitro leishmanicidal activity of monomeric and dimeric naphthoquinones. Acta Trop (2000) 77(3):307-314.
68. Lunardi F, Guzela M, Rodrigues AT, Correa R, Eger-Mangrich I, Steindel M, Grisard EC, Assreuy J, Calixto JB, Santos AR: Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob Agents Chemother (2003) 47(4):1449-1451.
69. Chen M, Zhai L, Christensen SB, Theander TG, Kharazmi A: Inhibition of fumarate reductase in Leishmania major and L donovani by chalcones. Antimicrob Agents Chemother (2001) 45(7):2023-2029.
70. Vennerstrom JL, Lovelace JK, Waits VB, Hanson WL, Klayman DL: Berberine derivatives as antileishmanial drugs. Antimicrob Agents Chemother (1990) 34(5):918-921.
71. Marquis JF, Makhey D, LaVoie EJ, Olivier M: Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function, and infection. J Parasitol (2003) 89(5):1048-1052.
72. Chen M, Christensen SB, Theander TG, Kharazmi A: Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob Agents Chemother (1994) 38(6):1339-1344.
73. Chen M, Christensen SB, Blom J, Lemmich E, Nadelmann L, Fich K, Theander TG, Kharazmi A: Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania. Antimicrob Agents Chemother (1993) 37(12):2550-2556.
74. Zhai L, Blom J, Chen M, Christensen SB, Kharazmi A: The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother (1995) 39(12):2742-2748.
75. Rao KV, Kasanah N, Wahyuono S, Tekwani BL, Schinazi RF, Hamann MT: Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases. J Nat Prod (2004) 67(8):1314-1318.
76. Torres-Santos EC, Lopes D, Oliveira RR, Carauta JP, Falcao CA, Kaplan MA, Rossi-Bergmann B: Antileishmanial activity of isolated triterpenoids from Pourouma guianensis. Phytomedicine (2004) 11(2-3):114-120.
77. Okpekon T, Yolou S, Gleye C, Roblot F, Loiseau P, Bories C, Grellier P, Frappier F, Laurens A, Hocquemiller R: Antiparasitic activities of medicinal plants used in Ivory Coast. J Ethnopharmacol (2004) 90(1):91-97.
78. Takahashi M, Fuchino H, Sekita S, Satake M: In vitro leishmanicidal activity of some scarce natural products. Phytother Res (2004) 18(7):573-578.
79. Maes L, Vanden Berghe D, Germonprez N, Quirijnen L, Cos P, De Kimpe N, Van Puyvelde L: In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species. Antimicrob Agents Chemother (2004) 48(1):130-136.
80. Di Giorgio C, Delmas F, Ollivier E, Elias R, Balansard G, Timon-David P: In vitro activity of the β-carboline alkaloids harmane, harmine, and harmaline toward parasites of the species Leishmania infantum. Exp Parasitol (2004) 106(3-4):67-74.
81. Luque-Ortega JR, Martinez S, Saugar JM, Izquierdo LR, Abad T, Luis JG, Pinero J, Valladares B, Rivas L: Fungus-elicited metabolites from plants as an enriched source for new leishmanicidal agents: Antifungal phenyl-phenalenone phytoalexins from the banana plant (Musa acuminata) target mitochondria of Leishmania donovani promastigotes. Antimicrob Agents Chemother (2004) 48(5):1534-1540.
82. Saleheen D, Ali SA, Yasinzai MM: Antileishmanial activity of aqueous onion extract in vitro. Fitoterapia (2004) 75(1):9-13.
83. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S: Antimalarial drug discovery: Efficacy models for compound screening. Nat Rev Drug Discov (2004) 3(6):509-520.
84. Muller S, Liebau E, Walter RD, Krauth-Siegel RL: Thiol-based redox metabolism of protozoan parasites. Trends Parasitol (2003) 19(7):320-328.
85. D'Silva C, Daunes S: The therapeutic potential of inhibitors of the trypanothione cycle. Expert Opin Investig Drugs (2002) 11(2):217-231.
86. Verlinde CL, Hannaert V, Blonski C, Willson M, Perie JJ, Fothergill-Gilmore LA, Opperdoes FR, Gelb MH, Hol WG, Michels PA: Glycolysis as a target for the design of new anti-trypanosome drugs. Drug Resistance Updates (2001) 4(1):50-65.
87. Moyersoen J, Choe J, Fan E, Hol WG, Michels PA: Biogenesis of peroxisomes and glycosomes: Trypanosomatid glycosome assembly is a promising new drug target. FEMS Microbiol Rev (2004) 28(5):603-643.
88. Mottram JC, Coombs GH, Alexander J: Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol (2004) 7(4):375-381.
89. Garami A, Ilg T: Disruption of mannose activation in Leishmania mexicana: GDP-mannose pyrophosphorylase is required for virulence, but not for viability. EMBO J (2001) 20(14):3657-3666.
90. Garami A, Mehlert A, Ilg T: Glycosylation defects and virulence phenotypes of Leishmania mexicana phosphomannomutase and dolicholphosphate- mannose synthase gene deletion mutants. Mol Cell Biol (2001) 21(23):8168-8183.
91. Davis AJ, Perugini MA, Smith BJ, Stewart JD, Ilg T, Hodder AN, Handman E: Properties of GDP-mannose pyrophosphorylase, a critical enzyme and drug target in Leishmania mexicana. J Biol Chem (2004) 279(13):12462-12468.
92. Yardley V, Khan AA, Martin MB, Slifer TR, Araujo FG, Moreno SN, Docampo R, Croft SL, Oldfield E: In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother (2002) 46(3):929-931.
93. Hunter WN: A structure-based approach to drug discovery; crystallography and implications for the development of antiparasite drugs. Parasitology (1997) 114(Suppl):S17-S29.
94. Austin SE, Khan MO, Douglas KT: Rational drug design using trypanothione reductase as a target for anti-trypanosomal and antileishmanial drug leads. Drug Des Discov (1999) 16(1):5-23.
95. Castro-Pinto DB, Echevarria A, Genestra MS, Cysne-Finkelstein L, Leon LL: Trypanothione reductase activity is prominent in metacyclic promastigotes and axenic amastigotes of Leishmania amazonesis. Evaluation of its potential as a therapeutic target. J Enzyme Inhib Med Chem (2004) 19(1):57-63.
96. Werbovetz KA: Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis. Curr Med Chem (2000) 7(8):835-860.
97. Dardonville C, Rinaldi E, Hanau S, Barrett MP, Brun R, Gilbert IH: Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem (2003) 11(14):3205-3214.
98. Bressi JC, Verlinde CL, Aronov AM, Shaw ML, Shin SS, Nguyen LN, Suresh S, Buckner FS, Van Voorhis WC, Kuntz ID, Hol WG, Gelb MH: Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J Med Chem (2001) 44(13):2080-2093.
99. Gilbert IH: Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim Biophys Acta (2002) 1587(2-3):249-257.
100. Atreya CE, Johnson EF, Irwin JJ, Dow A, Massimine KM, Coppens I, Stempliuk V, Beverley S, Joiner KA, Shoichet BK, Anderson KS: A molecular docking strategy identifies Eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase. J Biol Chem (2003) 278(16):14092-14100.
101. Zhang P, Nicholson DE, Bujnicki JM, Su X, Brendle JJ, Ferdig M, Kyle DE, Milhous WK, Chiang PK: Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J Biomed Sci (2002) 9(1):34-40.
102. Bleicher KH, Bohm HJ, Muller K, Alanine Al: Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Discov (2003) 2(5):369-378.
103. Walters WP, Namchuk M: Designing screens: How to make your hits a hit. Nat Rev Drug Discov (2003) 2(4):259-266.
104. St Hilaire PM, Alves LC, Sanderson SJ, Mottram JC, Juliano MA, Juliano L, Coombs GH, Meldal M: The substrate specificity of a recombinant cysteine protease from Leishmania mexicana: Application of a combinatorial peptide library approach. Chembiochem (2000) 1(2):115-122.
105. Graven A, St Hilaire PM, Sanderson SJ, Mottram JC, Coombs GH, Meldal M: Combinatorial library of peptide isosters based on Diels-Alder reactions: Identification of novel inhibitors against a recombinant cysteine protease from Leishmania mexicana. J Combinatorial Chem (2001) 3(5):441-452.
106. Tornoe CW, Sanderson SJ, Mottram JC, Coombs GH, Meldal M: Combinatorial library of peptidotriazoles: Identification of [1,2,3]-triazole inhibitors against a recombinant Leishmania mexicana cysteine protease. J Combinatorial Chem (2004) 6(3):312-324.
107. Labadie GR, Choi SR, Avery MA: Diamine derivatives with antiparasitic activities. Bioorg Med Chem Lett (2004) 14(3):615-619.
108. Hinshaw JC, Suh DY, Garnier P, Buckner FS, Eastman RT, Matsuda SP, Joubert BM, Coppens I, Joiner KA, Merali S, Nash TE, Prestwich GD: Oxidosqualene cyclase inhibitors as antimicrobial agents. J Med Chem (2003) 46(20):4240-4243.
109. Grant KM, Dunion MH, Yardley V, Skaltsounis AL, Marko D, Eisenbrand G, Croft SL, Meijer L, Mottram JC: Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: Chemical library screen and antileishmanial activity. Antimicrob Agents Chemother (2004) 48(8):3033-3042.